A Phase 2 Study of Neratinib and Neratinib Plus Temsirolimus in Patients With Non-Small Cell Lung Cancer Carrying Known HER2 Activating Mutations
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2018
At a glance
- Drugs Neratinib (Primary) ; Temsirolimus
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Puma Biotechnology
- 23 Jan 2018 This study is completed in France (06-Oct-2017).
- 06 Jul 2017 Planned End Date changed from 1 Mar 2017 to 1 Dec 2017.
- 28 Sep 2016 Planned End Date changed from 1 Dec 2016 to 1 Mar 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History